Metastatic Breast Cancer
Conference Coverage
CONCERT: Better QoL but not survival with cabazitaxel in metastatic HER2– breast cancer
Conference Coverage
ASCO 2021: Breast cancer sessions not to miss
Conference Coverage
IL-6 levels predict distant breast cancer recurrence
Conference Coverage
Trastuzumab deruxtecan-related lung disease in MBC patients can occur anytime in first year
Conference Coverage
Endocrine therapy benefits in premenopausal breast cancer differ by molecular risk
News
Evolving strategies in sequencing for HER2+ MBC therapy
In a 12-month window, the FDA approved four agents targeting HER2-positive MBC.
News
New targeted treatments are major advances for HER2-positive breast cancer
Conference Coverage
GELATO trial: Chemoimmunotherapy may help in metastatic invasive lobular breast cancer
News
FDA panel votes against 2 cancer indications but backs 4 of 6
At a 3-day meeting, an FDA advisory group considered the accelerated approvals of six cancer indications for three immunotherapies.
News
FDA panel backs atezolizumab for mTNBC – at least for now
FDA advisers voted to keep in place an approval for atezolizumab in metastatic triple-negative breast cancer.